INKT EBITDA | MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc. (INKT) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income -$3.22M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income -$2.88M; Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA (m); Operating income -$3.18M; Depreciation and amortization (m).
2025-06-30: Basis Reported; EBITDA (m); Operating income -$4.05M; Depreciation and amortization (m).

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	-$3.22M	(m)	(m)	(m)	(m)	-$2.08M*	(m)	$1.89M	(m)	(m)
2026-03-31	Reported	(m)	-$2.88M	(m)	(m)	(m)	(m)	-$1.73M	(m)	$1.20M	(m)	(m)
2025-09-30	Reported	(m)	-$3.18M	(m)	(m)	(m)	(m)	-$941.35K*	(m)	$1.14M	(m)	(m)
2025-06-30	Reported	(m)	-$4.05M	(m)	(m)	(m)	(m)	-$1.57M*	(m)	$1.84M	(m)	(m)
2025-03-31	Reported	(m)	-$2.70M	(m)	(m)	(m)	(m)	-$1.34M	(m)	$1.26M	(m)	(m)
2024-09-30	Reported	(m)	-$1.88M	(m)	(m)	(m)	(m)	-$2.99M*	(m)	$540.64K	(m)	(m)
2024-06-30	Reported	(m)	-$3.07M	(m)	(m)	(m)	(m)	-$2.29M*	(m)	$1.84M	(m)	(m)
2024-03-31	Reported	(m)	-$3.83M	(m)	(m)	(m)	(m)	-$2.54M	(m)	$2.55M	(m)	(m)
2023-09-30	Reported	(m)	-$5.22M	(m)	(m)	(m)	$23.04K*	-$4.21M*	(m)	$3.43M	(m)	(m)
2023-06-30	Reported	(m)	-$6.34M	(m)	(m)	(m)	$37.02K*	-$4.15M*	(m)	$4.56M	(m)	(m)
2023-03-31	Reported	(m)	-$5.85M	(m)	(m)	(m)	$13.50K	-$4.37M	(m)	$4.19M	(m)	(m)
2022-09-30	Reported	(m)	-$7.99M	(m)	(m)	(m)	$59.80K*	-$5.61M*	(m)	$6.15M	(m)	(m)
2022-06-30	Reported	(m)	-$7.70M	(m)	(m)	(m)	(m)	-$4.63M*	(m)	$5.88M	(m)	(m)
2022-03-31	Reported	(m)	-$7.37M	(m)	(m)	(m)	(m)	-$4.20M	(m)	$5.28M	(m)	(m)
2021-09-30	Reported	(m)	-$13.38M	(m)	(m)	(m)	$111.82K*	-$3.50M*	(m)	$3.33M	(m)	(m)
2021-06-30	Reported	(m)	-$5.61M	(m)	(m)	(m)	$97.92K*	-$3.42M*	(m)	$3.58M	(m)	(m)
2021-03-31	Reported	(m)	-$3.01M	(m)	(m)	(m)	$39.52K	-$4.21M	(m)	$3.10M	(m)	(m)
2020-09-30	Reported	(m)	-$5.92M	(m)	(m)	(m)	(m)	(m)	(m)	$2.50M	(m)	(m)

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	(m)	-$12.64M	(m)	(m)	(m)	(m)	-$5.93M	(m)	$5.76M	(m)	(m)
2024-12-31	Reported	(m)	-$11.29M	(m)	(m)	(m)	(m)	-$9.56M	(m)	$6.34M	(m)	(m)
2023-12-31	Reported	(m)	-$22.92M	(m)	(m)	(m)	$73.56K	-$15.76M	(m)	$15.49M	(m)	(m)
2022-12-31	Reported	(m)	-$30.95M	(m)	(m)	(m)	$250.05K	-$18.87M	(m)	$23.12M	(m)	(m)
2021-12-31	Reported	(m)	-$28.36M	(m)	(m)	(m)	$248.98K	-$12.83M	(m)	$13.97M	(m)	(m)
2020-12-31	Reported	(m)	-$14.64M	(m)	(m)	(m)	$95.21K	-$8.34M	(m)	$9.51M	(m)	(m)

Stock Name	Country	Market Cap	PE Ratio
Eloxx Pharmaceuticals, Inc. (ELOX)	United States	$0.065B
EXOZYMES INC. (EXOZ)	United States	$0.058B
BioAtla, Inc. (BCAB)	United States	$0.058B	-0.21
ImageneBio, Inc. (IMA)	United States	$0.056B	-1.31
BioStem Technologies, Inc. (BSEM)	United States	$0.069B
CHAMPIONS ONCOLOGY, INC. (CSBR)	United States	$0.070B	-68.02
Inmune Bio, Inc. (INMB)	United States	$0.056B	-2.48
Kalaris Therapeutics, Inc. (KLRS)	United States	$0.073B	-2.19
Tevogen Inc. (TVGN)	United States	$0.049B
Instil Bio, Inc. (TIL)	United States	$0.048B	-1.73